Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · CellCept

CellCept 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 9

HOS-085201 · Präparat HOS-083095

Tacrolimus In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co- administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by mycophenolate mofetil (see also section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202)

Wechselwirkungen · CellCept

CellCept 500 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 30

HOS-085275 · Präparat HOS-083095

Tacrolimus In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co- administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by mycophenolate mofetil (see also section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202)

Wechselwirkungen · CellCept

CellCept 1 g/5 ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 51

HOS-085338 · Präparat HOS-083095

Tacrolimus In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co- administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by mycophenolate mofetil (see also section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202)

Wechselwirkungen · CellCept

CellCept 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 74

HOS-085409 · Präparat HOS-083095

Tacrolimus In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co- administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by mycophenolate mofetil (see also section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202)

Wechselwirkungen · Norvir

Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 20

HOS-086309 · Präparat HOS-083284

Immunosupressants Cyclosporine, tacrolimus, everolimus Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of cyclosporine, tacrolimus or everolimus. Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202) everolimus (HOS-086310) cyclosporine (HOS-084512)

Wechselwirkungen · Norvir

Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53

HOS-086475 · Präparat HOS-083284

Immunosupressants Cyclosporine, tacrolimus, everolimus Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of cyclosporine, tacrolimus or everolimus. Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202) everolimus (HOS-086310) cyclosporine (HOS-084512)

Wechselwirkungen · Micardis

Micardis 20 mg tablets Micardis 40 mg tablets Micardis 80 mg tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-089046 · Präparat HOS-083769

As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia (see section 4.4). The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor blockers, non steroidal anti- inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) aldosterone (HOS-086926) trimethoprim (HOS-085184) heparin (HOS-086930) tacrolimus (HOS-085202) potassium (HOS-086929)

Wechselwirkungen · Renagel

Renagel 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-090092 · Präparat HOS-083991

Ciclosporin, mycophenolate mofetil and tacrolimus in transplant patients Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (i.e graft rejection). The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of mycophenolate mofetil, ciclosporin and tacrolimus should be considered during the use of combination and after its withdrawal.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sevelamer hydrochloride (HOS-090088) tacrolimus (HOS-085202) mycophenolate mofetil (HOS-085154)

Wechselwirkungen · Renagel

Renagel 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13

HOS-090107 · Präparat HOS-083991

Ciclosporin, mycophenolate mofetil and tacrolimus in transplant patients Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (i.e graft rejection). The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of mycophenolate mofetil, ciclosporin and tacrolimus should be considered during the use of combination and after its withdrawal.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sevelamer hydrochloride (HOS-090088) tacrolimus (HOS-085202) mycophenolate mofetil (HOS-085154)

Wechselwirkungen · Targretin

Targretin 75 mg soft capsules · Abschnitt 4.5 · PDF-Seite 5

HOS-091527 · Präparat HOS-084349

Caution is advised in case of combination with CYP3A4 substrates having a narrow therapeutic margin i.e. immunosuppressive agents (cyclosporine, tacrolimus, sirolimus) as well as CYP3A4-metabolised cytotoxics, i.e. cyclophosphamide, etoposide, finasteride, ifosfamide, tamoxifen, vinca-alcaloids.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): finasteride (HOS-091528) tamoxifen (HOS-088380) etoposide (HOS-086021) ifosfamide (HOS-091529) tacrolimus (HOS-085202) cyclophosphamide (HOS-084539) sirolimus (HOS-085172) cyclosporine (HOS-084512)

Wechselwirkungen · Aranesp

Aranesp 10 micrograms solution for injection in pre-filled syringe. Aranesp 15 micrograms solution for injection in pre-filled syringe. Aranesp 20 micrograms solution for injection in pre-filled syringe. Aranesp 30 micrograms solution for injection in pre-filled syringe. Aranesp 40 micrograms solution for injection in pre-filled syringe. Aranesp 50 micrograms solution for injection in pre-filled syringe. Aranesp 60 micrograms solution for injection in pre-filled syringe. Aranesp 80 micrograms solution for injection in pre-filled syringe. Aranesp 100 micrograms solution for injection in pre-filled syringe. Aranesp 130 micrograms solution for injection in pre-filled syringe. Aranesp 150 micrograms solution for injection in pre-filled syringe. Aranesp 300 micrograms solution for injection in pre-filled syringe. Aranesp 500 micrograms solution for injection in pre-filled syringe. Aranesp 10 micrograms solution for injection in pre-filled pen. Aranesp 15 micrograms solution for injection in pre-filled pen. Aranesp 20 micrograms solution for injection in pre-filled pen. Aranesp 30 micrograms solution for injection in pre-filled pen. Aranesp 40 micrograms solution for injection in pre-filled pen. Aranesp 50 micrograms solution for injection in pre-filled pen. Aranesp 60 micrograms solution for injection in pre-filled pen. Aranesp 80 micrograms solution for injection in pre-filled pen. Aranesp 100 micrograms solution for injection in pre-filled pen. Aranesp 130 micrograms solution for injection in pre-filled pen. Aranesp 150 micrograms solution for injection in pre-filled pen. Aranesp 300 micrograms solution for injection in pre-filled pen. Aranesp 500 micrograms solution for injection in pre-filled pen. Aranesp 25 micrograms solution for injection in vial. Aranesp 40 micrograms solution for injection in vial. Aranesp 60 micrograms solution for injection in vial. Aranesp 100 micrograms solution for injection in vial. Aranesp 200 micrograms solution for injection in vial. Aranesp 300 micrograms solution for injection in vial. · Abschnitt 4.5 · PDF-Seite 11

HOS-091571 · Präparat HOS-084365

The clinical results obtained so far do not indicate any interaction of darbepoetin alfa with other substances. However, there is potential for an interaction with substances that are highly bound to red blood cells e.g. cyclosporin, tacrolimus. If Aranesp is given concomitantly with any of these treatments, blood levels of these substances should be monitored and the dosage adjusted as the haemoglobin rises.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202)

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 23–24

HOS-108925 · Präparat HOS-093083

23 Glecaprevir/pibrentasvir Serum concentrations may be Concomitant administration of increased due to P-glycoprotein, glecaprevir/pibrentasvir and BCRP and OATP1B inhibition by Kaletra is not recommended due lopinavir/ritonavir. to an increased risk of ALT elevations associated with increased glecaprevir exposure. Sofosbuvir/velpatasvir/ Serum concentrations of It is not recommended to voxilaprevir sofosbuvir, velpatasvir and coadminister Kaletra and voxilaprevir may be increased due sofosbuvir/velpatasvir/ to P-glycoprotein, BCRP and voxilaprevir. OATP1B1/3 inhibition by lopinavir/ritonavir. However, only the increase in voxilaprevir exposure is considered clinically relevant. HCV protease inhibitors Simeprevir 200 mg daily Simeprevir: It is not recommended to (ritonavir 100 mg BID) AUC: ↑ 7.2-fold co-administer Kaletra and Cmax: ↑ 4.7-fold simeprevir. Cmin: ↑ 14.4-fold Herbal products St John’s wort (Hypericum Lopinavir: Herbal preparations containing St perforatum) Concentrations may be reduced John’s wort must not be combined due to induction of CYP3A by the with lopinavir and ritonavir. If a herbal preparation St John’s wort. patient is already taking St John’s wort, stop St John’s wort and if possible check viral levels. Lopinavir and ritonavir levels may increase on stopping St John’s wort. The dose of Kaletra may need adjusting. The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort (see section 4.3). Therefore, Kaletra can be started safely 2 weeks after cessation of St John's wort. Immunosuppressants Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic (rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is Tacrolimus Concentrations may be increased recommended until plasma levels due to CYP3A inhibition by of these products have been lopinavir/ritonavir. stabilised. Lipid lowering agents Lovastatin and Simvastatin Lovastatin, Simvastatin: Since increased concentrations of Markedly increased plasma HMG-CoA reductase inhibitors concentrations due to CYP3A may cause myopathy, including inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of these agents with Kaletra is contraindicated (see section 4.3). Lipid-modifying agents Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with exposure of lomitapide, with lomitapide is contraindicated (see strong inhibitors increasing prescribing information for exposure approximately 27-fold. lomitapide) (see section 4.3). Due to CYP3A inhibition by lopinavir/ritonavir, concentrations

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) protease (HOS-085623) lovastatin (HOS-086157) pibrentasvir (HOS-086298) lomitapide (HOS-086160) simvastatin (HOS-086158) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) tacrolimus (HOS-085202) velpatasvir (HOS-108929) simeprevir (HOS-086302) sirolimus (HOS-085172)

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60

HOS-109022 · Präparat HOS-093083

59 Herbal products St John’s wort Lopinavir: Herbal preparations containing St (Hypericum perforatum) Concentrations may be reduced John’s wort must not be combined due to induction of CYP3A by the with lopinavir and ritonavir. If a herbal preparation St John’s wort. patient is already taking St John’s wort, stop St John’s wort and if possible check viral levels. Lopinavir and ritonavir levels may increase on stopping St John’s wort. The dose of Kaletra may need adjusting. The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort (see section 4.3). Therefore, Kaletra can be started safely 2 weeks after cessation of St John's wort. Immunosuppressants Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic (rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is Tacrolimus Concentrations may be increased recommended until plasma levels of due to CYP3A inhibition by these products have been stabilised. lopinavir/ritonavir. Lipid lowering agents Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors may concentrations due to CYP3A cause myopathy, including inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of these agents with Kaletra is contraindicated (see section 4.3). Lipid-modifying agents Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with exposure of lomitapide, with lomitapide is contraindicated (see strong inhibitors increasing prescribing information for exposure approximately 27-fold. lomitapide) (see section 4.3). Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of lomitapide are expected to increase. Atorvastatin Atorvastatin: The combination of Kaletra with AUC: ↑ 5.9-fold atorvastatin is not recommended. If Cmax: ↑ 4.7-fold the use of atorvastatin is considered Due to CYP3A inhibition by strictly necessary, the lowest possible lopinavir/ritonavir. dose of atorvastatin should be administered with careful safety monitoring (see section 4.4). Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and AUC: ↑ 2-fold reduced doses should be considered Cmax: ↑ 5-fold when Kaletra is co-administered with While rosuvastatin is poorly rosuvastatin (see section 4.4). metabolised by CYP3A4, an increase of its plasma concentrations was observed. The mechanism of this interaction may result from inhibition of transport proteins. Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA Pravastatin reductase inhibitor is indicated,

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 95–96

HOS-109101 · Präparat HOS-093083

95 Immunosuppressants Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic (rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is Tacrolimus Concentrations may be increased recommended until plasma levels of due to CYP3A inhibition by these products have been stabilised. lopinavir/ritonavir. Lipid lowering agents Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors concentrations due to CYP3A may cause myopathy, including inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of these agents with Kaletra is contraindicated (see section 4.3). Lipid-modifying agents Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with exposure of lomitapide, with lomitapide is contraindicated (see strong inhibitors increasing prescribing information for exposure approximately 27-fold. lomitapide) (see section 4.3). Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of lomitapide are expected to increase. Atorvastatin Atorvastatin: The combination of Kaletra with AUC: ↑ 5.9-fold atorvastatin is not recommended. If Cmax: ↑ 4.7-fold the use of atorvastatin is considered Due to CYP3A inhibition by strictly necessary, the lowest lopinavir/ritonavir. possible dose of atorvastatin should be administered with careful safety monitoring (see section 4.4). Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and AUC: ↑ 2-fold reduced doses should be considered Cmax: ↑ 5-fold when Kaletra is co-administered While rosuvastatin is poorly with rosuvastatin (see section 4.4). metabolised by CYP3A4, an increase of its plasma concentrations was observed. The mechanism of this interaction may result from inhibition of transport proteins. Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA Pravastatin No clinical relevant interaction reductase inhibitor is indicated, expected. fluvastatin or pravastatin is Pravastatin is not metabolised by recommended. CYP450. Fluvastatin is partially metabolised by CYP2C9. Opioids Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary. QD Methadone Methadone: ↓ Monitoring plasma concentrations of methadone is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) buprenorphine (HOS-086193) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)

Gegenanzeigen · Protopic

Protopic 0.03% ointment · Abschnitt 4.3 · PDF-Seite 4

HOS-109229 · Präparat HOS-093151

Hypersensitivity to the active substance, macrolides in general, or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Protopic

Protopic 0.1% ointment · Abschnitt 4.3 · PDF-Seite 15

HOS-109243 · Präparat HOS-093151

Hypersensitivity to the active substance, macrolides in general, or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Protopic

Protopic 0.03% ointment · Abschnitt 4.5 · PDF-Seite 5

HOS-109230 · Präparat HOS-093151

Formal topical drug interaction studies with tacrolimus ointment have not been conducted.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Protopic

Protopic 0.03% ointment · Abschnitt 4.5 · PDF-Seite 5

HOS-109231 · Präparat HOS-093151

Tacrolimus is not metabolised in human skin, indicating that there is no potential for percutaneous interactions that could affect the metabolism of tacrolimus.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Protopic

Protopic 0.03% ointment · Abschnitt 4.5 · PDF-Seite 5

HOS-109232 · Präparat HOS-093151

Systemically available tacrolimus is metabolised via the hepatic Cytochrome P450 3A4 (CYP3A4). Systemic exposure from topical application of tacrolimus ointment is low (<1.0 ng/ml) and is unlikely to be affected by concomitant use of substances known to be inhibitors of CYP3A4. However, the possibility of interactions cannot be ruled out and the concomitant systemic administration of known CYP3A4 inhibitors (e.g. erythromycin, itraconazole, ketoconazole and diltiazem) in patients with widespread and/or erythrodermic disease should be done with caution.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoconazole (HOS-084513) itraconazole (HOS-084516) erythromycin (HOS-084514)

Wechselwirkungen · Protopic

Protopic 0.03% ointment · Abschnitt 4.5 · PDF-Seite 5

HOS-109235 · Präparat HOS-093151

Paediatric population An interaction study with protein-conjugated vaccine against Neisseria menigitidis serogroup C has been investigated in children aged 2-11 years. No effect on immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity has been observed (see section 5.1).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.